Home Cart Sign in  
Chemical Structure| 948557-43-5 Chemical Structure| 948557-43-5

Structure of Tie2 kinase inhibitor 1
CAS No.: 948557-43-5

Chemical Structure| 948557-43-5
Product Citations

Alternative Products

Product Details of Tie2 kinase inhibitor 1

CAS No. :948557-43-5
Formula : C26H21N3O2S
M.W : 439.53
SMILES Code : O=S(C1=CC=C(C2=NC(C3=CC=C4C=C(OC)C=CC4=C3)=C(C5=CC=NC=C5)N2)C=C1)C
Synonyms :
Tunica Interna Endothelial Cell Kinase 2 Inhibitor; Tie2 Kinase Inhibitor; Compound 5
MDL No. :MFCD18384977
InChI Key :SINQIEAULQKUPD-UHFFFAOYSA-N
Pubchem ID :23625762

Safety of Tie2 kinase inhibitor 1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tie2 kinase inhibitor 1

RTK

Isoform Comparison

Biological Activity

Target
  • Tie-2

    Tie-2, IC50:0.25 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
TDEC IR+ 2 μM 15 days Inhibit Tie2 signaling pathway, reduce proangiogenic features of TDEC IR+ PMC6817826
HUVEC 2 μM 15 days Inhibit Tie2 signaling pathway, reduce proangiogenic features of TDEC IR+ PMC6817826
Nalm-6 cells 0-200 μM 72 h Evaluate the cytotoxicity of Tie2 kinase inhibitor on Nalm-6 cells, results showed inhibitor induced cell death in a dose-dependent manner PMC6272096
human retinal microvascular ECs (HRMVECs) 10 µM 21 days Inhibition of TIE2 signaling to study its effect on microvascular morphology, resulting in thinner vessels with enhanced CLDN5 expression. PMC10866954
Human primary NF-PitNET cells 5 μM (IC50) 48 h 9 out of 12 samples responded to Tie2-KI with 20-55% reduction in cell viability. PMC9081903
Rat primary PitNET cells 5 μM (IC50) 48 h Tie2-KI significantly inhibited primary tumor cell proliferation and reduced P-Akt levels. PMC9081903
GH3 cells 5 μM (IC50) 48 h Evaluated the inhibitory effect of Tie2 kinase inhibitor on GH3 cell proliferation, showing >20% suppression. PMC9081903
Megakaryocytic progenitor (MP) cells 250 nM 3 days To evaluate the recovery effect of Tie2 inhibitor on rhCOMP-Ang1-induced suppression of GATA-1 expression, results showed that Tie2 inhibitor almost completely recovered GATA-1 expression PMC9887089
HUVECs 5 µM 48 h Inhibit TIE2 signaling pathway, reverse the pro-angiogenic effect of TIE2-high cervical cancer cells on HUVECs PMC9483782
cultured bone marrow-derived endothelial cells (cBEC) 1 mM To investigate the effect of Tie2 kinase inhibitor on Ang1-induced Notch signaling pathway, results showed that Tie2 inhibitor completely blocked Ang1-induced expression of Notch ligands Dll4 and Jag1. PMC6821596
TEM (TIE-2 expressing monocytes) 8 μM 36 h To evaluate the effect of Tie2 kinase inhibitor on the pro-angiogenic activity of TEM, results showed that the inhibitor significantly reduced the pro-angiogenic activity of TEM. PMC4359163

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice MatrigelTM plug assay Intraperitoneal injection 30 mg/kg Twice daily for 14 days Inhibit Tie2 signaling pathway, reduce proangiogenic features of TDEC IR+ in vivo PMC6817826
Mice K14-Cre;c-Ang1 and Col2.3-Cre;c-Ang1 transgenic mice Intraperitoneal injection 10 mg/kg Single injection To evaluate the recovery effect of Tie2 inhibitor on GATA-1 expression and platelet levels in transgenic mice, results showed that Tie2 inhibitor restored GATA-1 expression and platelet levels PMC9887089
Lewis rats Neuromyelitis optica (NMO) model Intraperitoneal injection 25 mg/kg Daily for 2 weeks Inhibiting Tie2 kinase resulted in partial loss of C16 peptide-mediated effects, while suppressing PI3K/Akt signaling reduced C16 peptide-mediated effects. In addition, activation of the αvβ3 integrin axis and Tie2 kinase promoted PI3K/Akt signaling. PMC6902286

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.38mL

2.28mL

1.14mL

22.75mL

4.55mL

2.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories